TY  - JOUR
AU  - Argüelles-Arias, Federico
AU  - Guerra Veloz, Maria Fernanda
AU  - Perea Amarillo, Raul
AU  - Vilches-Arenas, Angel
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belen
AU  - Chaaro Benallal, Dina
AU  - Benítez Roldán, Antonio
AU  - Merino, Vicente
AU  - Ramirez, Gabriel
AU  - Calleja-Hernández, Miguel Angel
AU  - Caunedo Álvarez, Angel
AU  - Romero Gómez, Manuel
PY  - 2017
DO  - 10.1097/MEG.0000000000000953
UR  - http://hdl.handle.net/10668/11576
T2  - European journal of gastroenterology & hepatology
AB  - Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy, yet...
LA  - en
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Biosimilar Pharmaceuticals
KW  - C-Reactive Protein
KW  - Colitis, Ulcerative
KW  - Crohn Disease
KW  - Drug Substitution
KW  - Female
KW  - Follow-Up Studies
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Severity of Illness Index
KW  - Time Factors
TI  - Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
TY  - research article
VL  - 29
ER  -